---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-069036"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:18:22.174610+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeuroOne Q3 product rev up 31% to $826K; net loss narrows to $2.8M; oneRF partnership term sheet signed

## Summary
- Product revenue $826K in Q3 FY2024 vs $630K in Q3 FY2023 (+31%); net loss $2.8M vs $3.5M.
- Cash and equivalents $1.6M at June 30, 2024; subsequent $2.65M private placement and $3M credit facility in Aug 2024.
- Non-binding term sheet with undisclosed global medtech company to distribute OneRF Ablation System.
- First OneRF ablation cases completed; CMS granted new ICD-10-PCS code effective Oct 1, 2024.
- Operating expenses reduced to $3.1M from $3.8M YoY.

## SEC filing metadata
- accession: 0001213900-24-069036
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390024069036/0001213900-24-069036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390024069036/ea0211181-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-069036
- JSON: https://secwatch.observer/filing/0001213900-24-069036.json
- Plain text: https://secwatch.observer/filing/0001213900-24-069036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.